Evidence map›Paper›PMID 17523772›Full record

ArticleClinical drug investigation2005

Quality of life in sexually active men with symptomatic benign prostatic hyperplasia : effects of treatment.

Mel P Daly

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical drug investigation, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Mel P DalySubAcute Unit, Geriatric Medicine, Greater Baltimore Medical Center, Baltimore, Maryland, USAJohns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Johns Hopkins Medicine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Quality of life (QOL), sexuality in particular, has become an important consideration in treatment decisions for men with lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH). To determine the impact of these conditions on sexual function and QOL in older men, this article provides a review of clinical data on the relationship between sexual dysfunction and symptom severity, effective clinical assessment, treatment options, and the influence of current therapies on sexual function and QOL. The various symptoms of BPH can adversely affect sexual functioning and therefore QOL. Moreover, there may be a direct association between symptom severity and sexual dysfunction that may affect QOL.Patients base their decisions regarding treatment choices for BPH more on anticipated relief of lower urinary tract symptoms and improved QOL (including sexual functioning) than on improvements in physical measures. Although medications and surgery may relieve LUTS, sexual dysfunction is a common adverse result. Newer pharmacological interventions such as specific alpha-adrenergic blocking agents like tamsulosin may help improve sexual function and QOL in men with symptomatic BPH.

Identifiers

PMID17523772
OpenAlexW2057672310

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.